Helen Owens

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment”.

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2019.11.002

N/A

0DataRank · unranked

17 citations

Keith T. Schmidt, Fatima Karzai, Cody J. Peer, Lisa M. Cordes, Cindy H. Chau +8 more

Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer

British Journal of Urology(2020)10.1111/bju.15227

N/A

0DataRank · unranked

13 citations

Fatima Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen +22 more

Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.05.005

N/A

0DataRank · unranked

3 citations

Ravi A. Madan, Marijo Bilušić, Helen Owens, Lisa M. Cordes, Jennifer L. Marté +5 more

Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e17044

N/A

0DataRank · unranked

1 citations

Shruti U. Gandhy, Fatima Karzai, Marijo Bilušić, Lisa M. Cordes, Helen Owens +8 more

Anaplastic features (AnaF) and DNA-damage repair pathway (DDR) mutations in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.92

N/A

0DataRank · unranked

0 citations

Ravi A. Madan, Marijo Bilušić, Lisa M. Cordes, Jennifer L. Marté, Helen Owens +6 more

Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.093

N/A

0DataRank · unranked

4 citations

Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +15 more

Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.130

N/A

0DataRank · unranked

3 citations

Mohammad Atiq, Renee N. Donahue, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +11 more

Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17033

N/A

0DataRank · unranked

3 citations

Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilušić, Jennifer L. Marté +15 more

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17046

N/A

0DataRank · unranked

1 citations

Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilušić +15 more

Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.207

N/A

0DataRank · unranked

0 citations

Meghali Goswami, Renee N. Donahue, Mohammad Atiq, Fatima Karzai, Marijo Bilušić +13 more